Investigating the safety of REVTx-99 in Participants With Allergic Rhinitis to Rye Grass Pollen
Latest Information Update: 27 Jul 2022
At a glance
- Drugs Glycopyranosyl lipid adjuvant (Primary)
- Indications Allergic rhinitis; Nasal congestion
- Focus Adverse reactions; Proof of concept
- Acronyms CLEAR
- Sponsors Revelation Biosciences
- 22 Jul 2022 Results published in the Revelation Biosciences Media Release.
- 14 Jul 2022 According to a Revelation Biosciences media release, company completed Database Lock for this study and Topline data is expected in the last week of July 2022.
- 13 Jun 2022 According to a Revelation Biosciences media release, Status changed from recruiting to active, no longer recruiting.